DATA from clinical trials evaluating anti-tNF agents Three anti-TNF agents have been studied and two of these agents are approved by the FDA for the treatment of AS: etanercept, infliximab and ...

2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

Against an increased risk USA/Canada 1152 biologic users versus 7306 MTX users Retrospective cohort study Infliximab, etanercept and adalimumab. Pooled hazard ratio for hematologic malignancy ...

It is the most common idiopathic inflammatory arthritis of childhood. Etanercept, adalimumab and infliximab are the three TNF-α agents used. Etanercept is a soluble TNF receptor fusion protein ...

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; ...

Rheumatoid arthritis – adlimumab, etanercept, infliximab, certolizumab pegol, golumumab, abatacept and tocilizumab [in progress, ID537] TA247 Tocilizumab for the treatment of rheumatoid arthritis ...